Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03854123
Other study ID # CHUBX 2014/02
Secondary ID
Status Completed
Phase
First received
Last updated
Start date September 21, 2018
Est. completion date September 23, 2020

Study information

Verified date February 2022
Source University Hospital, Bordeaux
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Little is known about old MS patients. In a previous work, systematic search in Bordeaux, Strasbourg and Dijon university hospital regional MS center databases European Database for Multiple Sclerosis (EDMUS) retrieved 2% of 75 years old or older Multiple Sclerosis (MS) patients in the 3 databases. Data analysis showed that MS may switch off in the very old patients with mild progression and very few relapses. The project is to continue this preliminary work and extend it with a systematic study of MS in the elderly. The scientific aims: To add new insights into long lasting MS natural history in the growing population of elderly patients with MS.


Description:

75 to 77 years old MS patients whose disease began at 65 years old or earlier will be retrieved from the "Observatoire français de la sclérose en plaques" (OFSEP) which includes more than 50 000 MS patients in France. Accuracy of these patients' data from 65 to 75 years old will be thereafter checked and completed in 3 French MS centers: Lyon, Rennes and Bordeaux, participating to this database directly from the patients' clinical files. From these 3 MS centers around 150 MS patients from 75 to 77 years old are expected to be analysed on site. The data wich will be retrieved for these patients are: irreversible disability status scale progression, relapses, Magnetic Resonance Imaging (MRI) data, CSF data, Lublin classification of type of MS, McDonald 2005 and 2010 criteria, date and age at beginning of progression, characteristics and modality of relapses and clinical impairment at the beginning of the disease, treatments used, treatment failures and side effects, co morbidity, Barthel index, EuroQol-5D (EQ-5D), cognitive impairment (SDMT test), social life data and socio economic data. To the investigator's knowledge this will be the first systematic description of very old MS patients with data on long term natural history of MS and characteristics in this population of elderly MS patients.


Recruitment information / eligibility

Status Completed
Enrollment 159
Est. completion date September 23, 2020
Est. primary completion date September 23, 2020
Accepts healthy volunteers No
Gender All
Age group 75 Years to 77 Years
Eligibility Inclusion Criteria: - Patients with McDonald 2001, 2005 or 2010 criteria of multiple sclerosis 75 to 77 years old MS patients at the time of inclusion - Patients whose beginning of MS was before 65 years old or 65 years old - Patients who signed OFSEP 's consent Exclusion Criteria: - Patients whose clinical data cannot be entered or for whom too much clinical data are missing - Alive patients older than 77 years or younger than 75 years the day of the inclusion in the study - Patients died before 65 years old

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
France CHU de Bordeaux - Pellegrin - service de neurologie Bordeaux
France Hôpital neurologique - Pierre Wertheimer Bron
France CHU de Rennes - service de neurologie Rennes

Sponsors (3)

Lead Sponsor Collaborator
University Hospital, Bordeaux Novartis, Observatoire Français de la sclérose en plaques (OFSEP)

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluation of MS evolution with disability progression (irreversible Disability Status Scale) in 75 to 77 years Old MS Patients from the age of 65 years-old to present time Time to reach the irreversible Kurtzke disability status scale (DSS) score 4, 6 and 7 At inclusion (day 0)
Secondary Frequency of clinical relapses in 75 years Old or Older MS Patients from the age of 65 years-old to present time At inclusion (day 0)
Secondary Description of the clinical characteristics at 75 years Old Clinical conversion to secondary progressive MS date At inclusion (day 0)
Secondary Description of the Cerebral MRI at 75 years Old Number of lesions on T2 sequence if <9, number of new T2 lesions, Number of Gadolinium enhancing lesions, T1-Hypointense Lesions (T1 Black Holes), MRI Barkhof Criteria and number of periventricular lesions if <3, At inclusion (day 0)
Secondary Description of the paraclinical characteristics at 75 years Old Distance walked (with or without help) At inclusion (day 0)
Secondary Description of the paraclinical characteristics at 75 years Old Barthel index At inclusion (day 0)
Secondary Socio-demographic data sex At inclusion (day 0)
Secondary Socio-demographic data age At inclusion (day 0)
Secondary Socio-demographic data department of residence At inclusion (day 0)
Secondary Description of the treatments at 75 years Old Treatments of multiple sclerosis At inclusion (day 0)
Secondary Description of the treatments at 75 years Old Failures treatments of multiple sclerosis At inclusion (day 0)
Secondary Description of the treatments at 75 years Old Side effects of treatments and other concomitant treatments At inclusion (day 0)
Secondary Measure of health-related quality of life at 75 years Old EQ-5D Instruments At inclusion (day 0)
Secondary Evaluation of cognitive functions at 75 years Old Symbol digit modalities test (SDMT) test At inclusion (day 0)
See also
  Status Clinical Trial Phase
Completed NCT05528666 - Risk Perception in Multiple Sclerosis
Completed NCT03608527 - Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis N/A
Recruiting NCT05532943 - Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis Phase 1/Phase 2
Completed NCT02486640 - Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
Completed NCT01324232 - Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis Phase 2
Completed NCT04546698 - 5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
Active, not recruiting NCT04380220 - Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
Completed NCT02835677 - Integrating Caregiver Support Into MS Care N/A
Completed NCT03686826 - Feasibility and Reliability of Multimodal Evoked Potentials
Recruiting NCT05964829 - Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis N/A
Withdrawn NCT06021561 - Orofacial Pain in Multiple Sclerosis
Completed NCT03653585 - Cortical Lesions in Patients With Multiple Sclerosis
Recruiting NCT04798651 - Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis N/A
Active, not recruiting NCT05054140 - Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis Phase 2
Completed NCT05447143 - Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis N/A
Recruiting NCT06195644 - Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients Phase 1
Completed NCT04147052 - iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis N/A
Completed NCT03594357 - Cognitive Functions in Patients With Multiple Sclerosis
Completed NCT03591809 - Combined Exercise Training in Patients With Multiple Sclerosis N/A
Completed NCT02845635 - MS Mosaic: A Longitudinal Research Study on Multiple Sclerosis